Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamemmay assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2022 /PRNewswire/ --Actinogen Medical Limited (ASX: ACW)is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inade...